Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tanespimycin |
| Synonyms | |
| Therapy Description |
Tanespimycin (17-AAG) is a HSP90 inhibitor, potentially leading to decreased tumor growth (PMID: 19601813, PMID: 32540783). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tanespimycin | 17-AAG|BMS-722782|KOS-953|CNF-1010 | HSP90 Inhibitor 35 | Tanespimycin (17-AAG) is a HSP90 inhibitor, potentially leading to decreased tumor growth (PMID: 19601813, PMID: 32540783). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK2 V617F JAK2 L902Q JAK2 R938E | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R938E in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 Y931C | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and Y931C in culture (PMID: 39091915). | 39091915 |
| TP53 L194F | breast cancer | sensitive | Tanespimycin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 |
| JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 L983F | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 L902Q | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L902Q in culture (PMID: 39091915). | 39091915 |
| TP53 R248Q | colorectal cancer | sensitive | Tanespimycin | Preclinical | Actionable | In a preclincal study, Tanespimycin (17-AAG) treatment reduced p-Stat3 expression, induced apoptosis, and inhibited tumor growth of mutagen induced colorectal cancer in a genetic mouse model expressing TP53 R248Q (PMID: 30107178). | 30107178 |
| TP53 del | colorectal cancer | decreased response | Tanespimycin | Preclinical | Actionable | In a preclincal study, Tanespimycin (17-AAG) treatment of mutagen induced colorectal cancer in a genetic mouse model with biallelic loss of TP53 was less effective than treatment of mice bearing a single allele with a TP53 R248Q mutation (PMID: 30107178). | 30107178 |
| JAK2 V617F JAK2 L902Q JAK2 E1028K | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and E1028K in culture (PMID: 39091915). | 39091915 |
| JAK2 V617F JAK2 L902Q JAK2 R947Q | hematologic cancer | sensitive | Tanespimycin | Preclinical - Cell culture | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R947Q in culture (PMID: 39091915). | 39091915 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST